News Cutia Therapeutics

Equities

2487

KYG2606C1006

Market Closed - Hong Kong S.E. Other stock markets 01:39:05 07/06/2024 pm IST			5-day change	1st Jan Change
6.6 ^HKD	+1.23%		-5.71%	-39.89%

31/05	Cutia Therapeutics Presents Acne Drug's Phase III Clinical Trial Results at Asian Dermatology Congress	MT
30/05	Cutia Therapeutics Obtains Clinical Trial Approval in China for Dermatitis Drug	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cutia Therapeutics Presents Acne Drug's Phase III Clinical Trial Results at Asian Dermatology Congress	31/05	MT
Cutia Therapeutics Obtains Clinical Trial Approval in China for Dermatitis Drug	30/05	MT
Cutia Therapeutics Announces Investigational New Drug Application of CU-10101 for Atopic Dermatitis Approved by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China	30/05	CI
Cutia Therapeutics' Unit Receives Jiangsu Drug Manufacturing Certificate	30/04	MT
Cutia Therapeutics Submits NDA for Androgenetic Alopecia Treatment Spray; Shares Jump 6%	30/04	MT
Cutia Therapeutics Submits New Drug Application for Cu-40102 (Topical Finasteride Spray) in Hong Kong, PRC	30/04	CI
Cutia Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Cutia Therapeutics' Atopic Dermatitis Drug's IND Application Accepted by China's NMPA	27/03	MT
Cutia Therapeutics Announces the Investigational New Drug Application of CU-10101 (Topical Novel Small Molecule Agent) for the Treatment of Mild to Moderate Atopic Dermatitis Accepted by the Center for Drug Evaluation of the National Medical Products Administration	27/03	CI
Cutia Therapeutics Included in Two FTSE Indices	18/03	MT
Cutia Therapeutics Announces Completion of Phase I Clinical Trial of CU-20401	28/02	CI
Cutia Therapeutics Included in Hang Seng Family of Indexes	20/02	MT
Cutia's Phase 3 Clinical Trial for Analgesic Cream Reaches Primary Endpoint; Shares Surge 12%	31/01	MT
China Accepts Cutia Therapeutics's New Drug Application for Alopecia Treatment; Shares Surge 13%	31/01	MT
Cutia Therapeutics Announces New Drug Application for CU-40102 (Topical Finasteride Spray) Accepted by the National Medical Products Administration	31/01	CI
Cutia Therapeutics Doses First Patient for Anti-Obesity Injectable	03/01	MT
Cutia Therapeutics Announces First Patient Enrollment in the Phase II Clinical Trial of CU-20401	03/01	CI
Cutia Therapeutics Publishes Results of Phase 3 Trial for Alopecia, Acne Treatments in China	11/12	MT
Cutia Therapeutics Announces Results of Phase III Clinical Trials of CU-40102 (Topical Finasteride Spray) and CU-10201 (Topical 4% Minocycline Foam) in the People's Republic of China	11/12	CI
Certain Ordinary Shares of Cutia Therapeutics are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	11/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cutia Therapeutics

Equities

2487

KYG2606C1006

Summary

Filters